Literature DB >> 3099271

Use of polydioxanone absorbable monofilament sutures in orthopedic surgery.

J S Miles.   

Abstract

The safety and efficacy of polydioxanone absorbable monofilament sutures was documented in 57 orthopedic surgery patients (32, dyed sutures; 25, undyed sutures), 55 of whom were followed for at least 42 days postoperatively. The other two patients were lost to follow up prior to 42 days. The final clinical outcome was excellent in all completed study subjects. No suture-related adverse effects were reported. Both dyed and undyed sutures were consistently better than surgical gut with respect to pliability, strength, ease of passage, ease of tying, fraying, knot security, and overall handling. Intraoperative visibility of dyed polydioxanone sutures was consistently superior to that of surgical gut. The visibility of undyed sutures was rated better than surgical gut in 16 cases, equal in 8, and worse in 1. Both the overall handling of the polydioxanone monofilament sutures and performance as it affected wound healing were significantly superior to those of surgical gut.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099271     DOI: 10.3928/0147-7447-19861101-09

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  2 in total

1.  Evaluation of the safety and efficacy of MonoMax® suture material for abdominal wall closure after primary midline laparotomy-a controlled prospective multicentre trial: ISSAAC [NCT005725079].

Authors:  Markus Albertsmeier; Christoph M Seiler; Lars Fischer; Petra Baumann; Johannes Hüsing; Christoph Seidlmayer; Annette Franck; Karl-Walter Jauch; Hanns-Peter Knaebel; Markus W Büchler
Journal:  Langenbecks Arch Surg       Date:  2011-12-20       Impact factor: 3.445

2.  A historically controlled, single-arm, multi-centre, prospective trial to evaluate the safety and efficacy of MonoMax suture material for abdominal wall closure after primary midline laparotomy. ISSAAC-Trial [NCT005725079].

Authors:  Lars Fischer; Petra Baumann; Johannes Hüsing; Christoph Seidlmayer; Markus Albertsmeier; Annette Franck; Steffen Luntz; Christoph M Seiler; Hanns-Peter Knaebel
Journal:  BMC Surg       Date:  2008-07-21       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.